About Protein sidekick-2
Protein sidekick-2 (SDK2) is a protein
from Homo sapiens identified by UniProt accession
Q58EX2, 2172 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | Protein sidekick-2 |
|---|
| UniProt accession | Q58EX2 |
|---|
| Gene | SDK2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2172 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (26)
Diseases linked to this target (Open Targets).
- body mass index · score 0.35
- brain measurement · score 0.32
- diffuse plaque measurement · score 0.31
- microscopic polyangiitis · score 0.26
- white matter microstructure measurement · score 0.19
- PHF-tau measurement · score 0.12
- DNA methylation · score 0.09
- p-cresol sulfate measurement · score 0.08
- lean body mass · score 0.07
- fat body mass · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q58EX2-F1 | alphafold | PREDICTED | 72.79 | — |
Amino-acid sequence (2172 residues)
MWGLLIWTLL ALHQIRAARA QDDVSPYFKT EPVRTQVHLE GNRLVLTCMA EGSWPLEFKW LHNNRELTKF SLEYRYMITS LDRTHAGFYR CIVRNRMGAL LQRQTEVQVA YMGSFEEGEK HQSVSHGEAA VIRAPRIASF PQPQVTWFRD GRKIPPSSRI AITLENTLVI LSTVAPDAGR YYVQAVNDKN GDNKTSQPIT LTVENVGGPA DPIAPTIIIP PKNTSVVAGT SEVTLECVAN ARPLIKLHII WKKDGVLLSG GISDHNRRLT IPNPTGSDAG YYECEAVLRS SSVPSVVRGA YLSVLEPPQF VKEPERHITA EMEKVVDIPC QAKGVPPPSI TWYKDAAVVE VEKLTRFRQR NDGGLQISGL VPDDTGMFQC FARNAAGEVQ TSTYLAVTSI APNITRGPLD STVIDGMSVV LACETSGAPR PAITWQKGER ILASGSVQLP RFTPLESGSL LISPTHISDA GTYTCLATNS RGVDEASADL VVWARTRITK PPQDQSVIKG TQASMVCGVT HDPRVTIRYI WEKDGATLGT ESHPRIRLDR NGSLHISQTW SGDIGTYTCR VISAGGNDSR SAHLRVRQLP HAPEHPVATL STVERRAINL TWTKPFDGNS PLIRYILEMS ENNAPWTVLL ASVDPKATSV TVKGLVPARS YQFRLCAVND VGKGQFSKDT ERVSLPEEPP TAPPQNVIAS GRTNQSIMIQ WQPPPESHQN GILKGYIIRY CLAGLPVGYQ FKNITDADVN NLLLEDLIIW TNYEIEVAAY NSAGLGVYSS KVTEWTLQGV PTVPPGNVHA EATNSTTIRF TWNAPSPQFI NGINQGYKLI AWEPEQEEEV TMVTARPNFQ DSIHVGFVSG LKKFTEYFTS VLCFTTPGDG PRSTPQLVRT HEDVPGPVGH LSFSEILDTS LKVSWQEPGE KNGILTGYRI SWEEYNRTNT RVTHYLPNVT LEYRVTGLTA LTTYTIEVAA MTSKGQGQVS ASTISSGVPP ELPGPPTNLG ISNIGPRSVT LQFRPGYDGK TSISRWLVEA QVGVVGEGEE WLLIHQLSNE PDARSMEVPD LNPFTCYSFR MRQVNIVGTS PPSQPSRKIQ TLQAPPDMAP ANVSLRTASE TSLWLRWMPL PEMEYNGNPE SVGYKIKYSR SDGHGKTLSH VVQDRVERDY TIEDLEEWTE YRVQVQAFNA IGSGPWSQTV VGRTRESVPS SGPTNVSALA TTSSSMLVRW SEVPEADRNG LVLGYKVMYK EKDSDTQPRF WLVEGNSSRS AQLTGLGKYV LYEVQVLAFT RIGDGSPSHP PILERTLDDV PGPPMGILFP EVRTTSVRLI WQPPAAPNGI ILAYQITHRL NTTTANTATV EVLAPSARQY TATGLKPESV YLFRITAQTR KGWGEAAEAL VVTTEKRDRP QPPSRPMVQQ EDVRARSVLL SWEPGSDGLS PVRYYTIQTR ELPSGRWALH SASVSHNASS FIVDRLKPFT SYKFRVKATN DIGDSEFSEE SESLTTLQAA PDEAPTILSV TPHTTTSVLI RWQPPAEDKI NGILLGFRIR YRELLYEGLR GFTLRGINNP GATWAELTSM YSMRNLSRPS LTQYELDNLN KHRRYEIRMS VYNAVGEGPS SPPQEVFVGE AVPTAAPRNV VVHGATATQL DVTWEPPPLD SQNGDIQGYK IYFWEAQRGN LTERVKTLFL AENSVKLKNL TGYTAYMVSV AAFNAAGDGP RSTPTQGQTQ QAAPSAPSSV KFSELTTTSV NVSWEAPQFP NGILEGYRLV YEPCSPVDGV SKIVTVDVKG NSPLWLKVKD LAEGVTYRFR IRAKTFTYGP EIEANVTTGP GEGAPGPPGV PIIVRYSSAI AIHWSSGDPG KGPITRYVIE ARPSDEGLWD ILIKDIPKEV SSYTFSMDIL KPGVSYDFRV IAVNDYGFGT PSSPSQSVPA QKANPFYEEW WFLVVIALVG LIFILLLVFV LIIRGQSKKY AKKTDSGNSA KSGALGHSEM MSLDESSFPA LELNNRRLSV KNSFCRKNGL YTRSPPRPSP GSLHYSDEDV TKYNDLIPAE SSSLTEKPSE ISDSQGSDSE YEVDSNHQKA HSFVNHYISD PTYYNSWRRQ QKGISRAQAY SYTESDSGEP DHTTVTNSTS TQQGSLFRPK ASRTPTPQNP PNPPSQQSTL YRPPSSLAPG SRAPIAGFSS FV
Explore Protein sidekick-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets